Rolimus 5mg tablets are mainly indicated for the treatment of Renal carcinoma. Rolimus 5mg tablets are mainly indicated for the treatment of Breast carcinoma. Rolimus 5mg tablets are mainly indicated for the treatment of Brain carcinoma. Rolimus 5mg is also used in various advanced stage cancer in stomach, intestines or pancreas.
Everolimus is an mTOR prohibitor, joints at high compatibility to FK506 binding protein 12, via producing drug complex which inhibits the specific of mTOR. This inhibition decreases the activity of effectors downstream, that may cause blockage of cell progression from G1 into S phase, subsequently causes cell growth arrest and apoptosis
Brand : Rolimus
Ingredients : Everolimus
Strength : 5mg
Manufactured : Cipla
Package : 10 tablets in 1 strips
In breast cancer, renal cell cancer, pancreatic cancer, Neuro endocrine cancer: The prescribed dosage is 10mg should be taken as a single dose. In Brain or intracranial cancer: The prescribed dosage of Rolimus is 4.5mg/m2 orally as a single dose. In pediatric: The usual pediatric dosage of Rolimus in brain or intracranial tumor is 4.5mg/m2 should be taken orally as a single dose. Rolimus tablets should be administered with or without food.OVERDOSE
The over dosage of Everolimus is rarely occur, in case of over dosage patient must be provide with supportive measures. The acute toxicity of Everolimus over dosage should be monitored.
Hypersensitivity reactions, Lymphomas & other malignancy, Serious infections, Kidney graft thrombosis, Hepatic artery thrombosis, Nephrotoxicity, Hyperlipemia, Angioedema, Interstitial lung disease, Thrombocytopenia, Male infertility, Proteinuria, New commencement of diabetes
Increased exposure of skin cancers, patient may protect from UV lightSerious infections
Patients receiving Rolimus 5mg have high risk of acquiring various infections related to bacteria, virus, and fungi. Anti-microbial agents are preferred for the suspected patients.Hepatic artery thrombosis
In liver transplant patients, Rolimus 5mg therapy should not be recommended.Nephrotoxicity
Renal function should be monitored frequently; caution should be taken while using Rolimus 5mg in renal impaired patients.Angioedema
This may have occurred in the patients receiving concomitantly Rolimus 5mg with Angiotensin converting enzyme agentsHyperlipidemia
Patient getting Rolimus 5mg with lipid lowering drugs causes increasing in plasma concentration of these drugs causes hyperlipidemiaInterstitial lung disease
Occurred in Rolimus 5mg therapyInteract with grape juice
Causes increasing blood levels of Everolimus; avoid these concomitants.